Dr. Braddock is a hematopathologist and biochemist at Yale University, where he has practiced hematopathology and led a laboratory since 2004. His laboratory's focus is the study severe poorly addressed human disease with an emphasis on the elucidation of disease pathogenesis to unveil therapeutic targets. The laboratory is particularly interested in rare diseases of children, and in the design and engineering of novel biologics to modulate disease outcome. He is the scientific founder of Inozyme, whose lead asset, which was developed in Dr. Braddock’s lab, is now in phase 3 clinical trials in two lead indications.